HK1095733A1 - Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis - Google Patents

Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis

Info

Publication number
HK1095733A1
HK1095733A1 HK07101052.6A HK07101052A HK1095733A1 HK 1095733 A1 HK1095733 A1 HK 1095733A1 HK 07101052 A HK07101052 A HK 07101052A HK 1095733 A1 HK1095733 A1 HK 1095733A1
Authority
HK
Hong Kong
Prior art keywords
atherosclerosis
preventive
agent
serum cholesterol
cholesterol lowering
Prior art date
Application number
HK07101052.6A
Other languages
English (en)
Inventor
Hiroshi Tomiyama
Masayuki Yokota
Kazuhiro Kosakai
Original Assignee
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Pharmaceutical Co Ltd filed Critical Kotobuki Pharmaceutical Co Ltd
Publication of HK1095733A1 publication Critical patent/HK1095733A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07101052.6A 2003-06-27 2007-01-30 Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis HK1095733A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003185171A JP2005015434A (ja) 2003-06-27 2003-06-27 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
PCT/JP2004/008678 WO2005000353A1 (ja) 2003-06-27 2004-06-15 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤

Publications (1)

Publication Number Publication Date
HK1095733A1 true HK1095733A1 (en) 2007-05-18

Family

ID=33549648

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101052.6A HK1095733A1 (en) 2003-06-27 2007-01-30 Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis

Country Status (16)

Country Link
US (1) US7795229B2 (pt)
EP (1) EP1655037B1 (pt)
JP (1) JP2005015434A (pt)
KR (1) KR100792098B1 (pt)
CN (1) CN1812812B (pt)
AU (1) AU2004251536B2 (pt)
BR (1) BRPI0411723B1 (pt)
CA (1) CA2529452C (pt)
DK (1) DK1655037T3 (pt)
ES (1) ES2545667T3 (pt)
HK (1) HK1095733A1 (pt)
MX (1) MXPA05014084A (pt)
NO (1) NO335222B1 (pt)
PT (1) PT1655037E (pt)
RU (1) RU2328307C2 (pt)
WO (1) WO2005000353A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
WO2007001975A1 (en) 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
HU226822B1 (en) 1995-10-31 2009-11-30 Schering Corp Hypocholesterolemic sugar-substituted 2-azetidinones, and pharmaceutical compns. contg. them
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
CZ302193B6 (cs) 2000-12-20 2010-12-08 Schering Corporation 2-azetidinonové deriváty, substituované zbytkem cukru
ES2290562T3 (es) * 2001-01-26 2008-02-16 Schering Corporation Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares.
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Also Published As

Publication number Publication date
MXPA05014084A (es) 2006-03-17
EP1655037A1 (en) 2006-05-10
CN1812812B (zh) 2010-11-03
DK1655037T3 (en) 2015-08-24
RU2328307C2 (ru) 2008-07-10
PT1655037E (pt) 2015-10-19
BRPI0411723A (pt) 2006-08-08
EP1655037A4 (en) 2010-04-28
WO2005000353A1 (ja) 2005-01-06
BRPI0411723B1 (pt) 2016-08-02
AU2004251536A1 (en) 2005-01-06
RU2006102355A (ru) 2006-07-27
JP2005015434A (ja) 2005-01-20
US20060154876A1 (en) 2006-07-13
NO20060366L (no) 2006-01-23
EP1655037B1 (en) 2015-08-05
CA2529452A1 (en) 2005-01-06
KR100792098B1 (ko) 2008-01-04
NO335222B1 (no) 2014-10-20
ES2545667T3 (es) 2015-09-14
KR20060012032A (ko) 2006-02-06
CN1812812A (zh) 2006-08-02
CA2529452C (en) 2011-02-15
US7795229B2 (en) 2010-09-14
AU2004251536B2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
HK1095733A1 (en) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis
HUS2000033I1 (hu) Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
HUP0100388A3 (en) Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol
ZA200509136B (en) System and method for automatically completing spread-sheet formulas
ZA200308718B (en) Improved edible compositions for lowering cholesterol.
EP1602372A4 (en) MEDICAMENT ENHANCING THE PROGNOSIS OF ARACHNOIDAL HEMORRHAGE
TW566594U (en) Console drive
AU2003300440A8 (en) Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
AU2003221042A1 (en) Preventive or therapeutic agent for kidney disease
GB0427189D0 (en) Cholesterol assay
AU2003257051A8 (en) Composition and method for lowering cholesterol
AU2003277598A1 (en) Treating agent for masonry
HK1050316A1 (zh) 膽固醇降低劑
AU2939000A (en) Preventive or therapeutic agents for inflammatory dermatoses
EP1776956A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT FOR CALCIPENIA
GB2380481B (en) Means for treatment of atherosclerosis
GB0405123D0 (en) Driveshaft plunging units
GB2406130B (en) Safety panel
AU2001253233A1 (en) Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
AU2003205100A1 (en) Novel cholesterol absorption lowering agents
GB2391422B (en) Relay apparatus
AU2002356540A1 (en) Methods for combating bio-terrorism
PL359732A1 (en) Equipment designed for disintegrated waste roasting
AU2003210329A1 (en) Agent for inducing or inhibiting an angiogenesis
AU2002236306A1 (en) Remedies for nerve damages

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160615